RxDoctor Payments DataLook up a doctor →

Theodore Plush, DO

Critical Care Medicine · Camden, NJNPI 1710271895

Payments from drug & device makers

$63,476in general payments, 2019–2025

Across 442 payments — averaging $143.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$41K
  • Boehringer Ingelheim$5K
  • Astrazeneca UK Limited$5K
  • Intuitive Surgical$5K
  • GSK$2K
  • Johnson & Johnson$2K
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$5,16029%
  • Travel & lodging$2,03611%
  • Food & beverage$6,60037%
  • Education$4,17123%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,476 in reported general payments places this provider in the 95th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$557,481
Medicare patients
687
Services billed
11,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter552$447,254
Dupixent PenDupilumab50$188,389
Breztri AerosphereBudesonide/Glycopyr/Formoterol209$163,716
NucalaMepolizumab40$162,168
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr66$50,512
Spiriva RespimatTiotropium Bromide55$33,908
Breo ElliptaFluticasone/Vilanterol67$32,804
Incruse ElliptaUmeclidinium Bromide87$30,941
EliquisApixaban27$24,589
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$21,170
Bevespi AerosphereGlycopyrrolate/Formoterol Fum26$12,794
Albuterol Sulfate HfaAlbuterol Sulfate410$12,391
Combivent RespimatIpratropium/Albuterol Sulfate11$12,234
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$9,872
Fluticasone-SalmeterolFluticasone Propion/Salmeterol75$9,584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,626$732,930846 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$41,132$186,070274 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$5,413$67,31397 claims
PfizerEliquis$25$24,58927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 254 critical care medicine providers in New Jersey.

Other critical care medicine in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →